The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

The restructuring follows the company's receipt of a letter from the FDA citing "deficiencies" in its approval application for diabetes drug Zynquista.

Today, a brief rundown of news involving Halozyme and Neurogene, as well as updates from Argenx and Kura Oncology that you may have missed. BioNTech’s buyout of Biotheus fits a pattern common to ...

In buying Westlake-backed Kate Therapeutics, Novartis gets a handful of preclinical gene therapies targeting diseases like ...

Venture capital firms incubate, grow and finance dozens of drug companies each year. Follow the money they channel into the ...

The startup, Pep2Tango, is combining four methods of accelerating weight loss into one medicine in the hopes of developing a ...

Howard Chang will take over as chief scientific officer and senior VP of research as the biotech searches for more ways to ...

Built around research by Stanford scientist Carolyn Bertozzi and MIT researcher Jessica Stark, Valora Therapeutics is ...

Negative results from a Huntington’s trial add to a calamitous year for Sage, which last month decided to overhaul its ...

Analysts see Trump’s victory raising the high-profile legislation’s chances of becoming law. But the realities of a lame duck ...

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...